What happened: A recent major review has concluded that expensive Alzheimer’s drugs, costing around £90,000, offer minimal benefits that are unlikely to be noticeable to patients.
Why it matters:
- Raises questions about the value and cost-effectiveness of these high-priced treatments.
- Impacts patients, healthcare providers, and funding decisions in dementia care.
MNN Take: The report highlights concerns over whether the benefits of these costly drugs justify their price, prompting discussions about treatment priorities and resource allocation in Alzheimer’s care.
Sources: BBC Health (Lifestyle)